Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Allen, DB, Backeljauw, P, Bidlingmaier, M, Biller, BMK, Boguszewski, M, Burman, P, Butler, G, Chihara, K, Christiansen, J, Cianfarani, S, Clayton, P, Clemmons, D, Cohen, P, Darendeliler, F, Deal, C, Dunger, D, Erfurth, EM, Fuqua, JS, Grimberg, A, Haymond, M, Higham, C, Ho, K, Hoffman, AR, Hokken-Koelega, A, Johannsson, G, Juul, A, Kopchick, J, Lee, P, Pollak, M, Radovick, S, Robison, L, Rosenfeld, R, Ross, RJ, Savendahl, L, Saenger, P, Toft Sorensen, H, Stochholm, K, Strasburger, C, Swerdlow, A & Thorner, M 2015, 'GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults', European journal of endocrinology / European Federation of Endocrine Societies, bind 174, nr. 2, s. P1-9. https://doi.org/10.1530/EJE-15-0873

APA

Allen, D. B., Backeljauw, P., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Burman, P., Butler, G., Chihara, K., Christiansen, J., Cianfarani, S., Clayton, P., Clemmons, D., Cohen, P., Darendeliler, F., Deal, C., Dunger, D., Erfurth, E. M., Fuqua, J. S., Grimberg, A., ... Thorner, M. (2015). GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. European journal of endocrinology / European Federation of Endocrine Societies, 174(2), P1-9. https://doi.org/10.1530/EJE-15-0873

CBE

Allen DB, Backeljauw P, Bidlingmaier M, Biller BMK, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen J, Cianfarani S, Clayton P, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger D, Erfurth EM, Fuqua JS, Grimberg A, Haymond M, Higham C, Ho K, Hoffman AR, Hokken-Koelega A, Johannsson G, Juul A, Kopchick J, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger C, Swerdlow A, Thorner M. 2015. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. European journal of endocrinology / European Federation of Endocrine Societies. 174(2):P1-9. https://doi.org/10.1530/EJE-15-0873

MLA

Vancouver

Author

Allen, D B ; Backeljauw, P ; Bidlingmaier, M ; Biller, B M K ; Boguszewski, M ; Burman, P ; Butler, Graham ; Chihara, K ; Christiansen, J ; Cianfarani, S ; Clayton, P ; Clemmons, D ; Cohen, P ; Darendeliler, F ; Deal, C ; Dunger, D ; Erfurth, E M ; Fuqua, J S ; Grimberg, A ; Haymond, M ; Higham, C ; Ho, K ; Hoffman, A R ; Hokken-Koelega, A ; Johannsson, G ; Juul, A ; Kopchick, J ; Lee, P ; Pollak, M ; Radovick, S ; Robison, L ; Rosenfeld, R ; Ross, R J ; Savendahl, L ; Saenger, P ; Toft Sorensen, H ; Stochholm, K ; Strasburger, C ; Swerdlow, A ; Thorner, M. / GH safety workshop position paper : a critical appraisal of recombinant human GH therapy in children and adults. I: European journal of endocrinology / European Federation of Endocrine Societies. 2015 ; Bind 174, Nr. 2. s. P1-9.

Bibtex

@article{e51931b69d7b4e5189c7b61448b7a86e,
title = "GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults",
abstract = "Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.",
author = "Allen, {D B} and P Backeljauw and M Bidlingmaier and Biller, {B M K} and M Boguszewski and P Burman and Graham Butler and K Chihara and J Christiansen and S Cianfarani and P Clayton and D Clemmons and P Cohen and F Darendeliler and C Deal and D Dunger and Erfurth, {E M} and Fuqua, {J S} and A Grimberg and M Haymond and C Higham and K Ho and Hoffman, {A R} and A Hokken-Koelega and G Johannsson and A Juul and J Kopchick and P Lee and M Pollak and S Radovick and L Robison and R Rosenfeld and Ross, {R J} and L Savendahl and P Saenger and {Toft Sorensen}, H and K Stochholm and C Strasburger and A Swerdlow and M Thorner",
note = "{\textcopyright} 2016 The authors.",
year = "2015",
month = feb,
doi = "10.1530/EJE-15-0873",
language = "English",
volume = "174",
pages = "P1--9",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - GH safety workshop position paper

T2 - a critical appraisal of recombinant human GH therapy in children and adults

AU - Allen, D B

AU - Backeljauw, P

AU - Bidlingmaier, M

AU - Biller, B M K

AU - Boguszewski, M

AU - Burman, P

AU - Butler, Graham

AU - Chihara, K

AU - Christiansen, J

AU - Cianfarani, S

AU - Clayton, P

AU - Clemmons, D

AU - Cohen, P

AU - Darendeliler, F

AU - Deal, C

AU - Dunger, D

AU - Erfurth, E M

AU - Fuqua, J S

AU - Grimberg, A

AU - Haymond, M

AU - Higham, C

AU - Ho, K

AU - Hoffman, A R

AU - Hokken-Koelega, A

AU - Johannsson, G

AU - Juul, A

AU - Kopchick, J

AU - Lee, P

AU - Pollak, M

AU - Radovick, S

AU - Robison, L

AU - Rosenfeld, R

AU - Ross, R J

AU - Savendahl, L

AU - Saenger, P

AU - Toft Sorensen, H

AU - Stochholm, K

AU - Strasburger, C

AU - Swerdlow, A

AU - Thorner, M

N1 - © 2016 The authors.

PY - 2015/2

Y1 - 2015/2

N2 - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

AB - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

U2 - 10.1530/EJE-15-0873

DO - 10.1530/EJE-15-0873

M3 - Journal article

C2 - 26563978

VL - 174

SP - P1-9

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -

ID: 45922167